Celyad advances first NKG2D CAR T-Cell Phase I study
Celyad advances first NKG2D CAR T-Cell Phase I study
Pharmaceuticals, Biotechnology and Life Sciences
Celyad advances first NKG2D CAR T-Cell Phase I study
Biophytis has appointed Pierre J. Dilda, PhD, as Director of
Research.
Neovacs, a France-based specialist in active immunotherapies for the treatment of autoimmune diseases, has decided to engage in the field of immuno-oncology after a recommendations by its Scientific Adivsory Board
Funding for tuberculosis research fell $1.3 billion short of global targets last year, threatening worldwide goals to eliminate the disease between 2030 and 2035, researchers said on Monday.
Velneva’s Clostridium difficile vaccine Candidate meets Phase II trial target
Horizon Pharma and its affiliate, Horizon Therapeutics, has gotten the European Commission’s (EC’s) approval for Ravicti – glycerol phenylbutyrate – Oral Liquid for use as an adjunctive therapy for chronic management patients with six subtypes of Urea Cycle Disorders (UCDs).
Boston-based PureTech Health plc has launched a Scientific Advisory Board (SAB) of distinguished scientists and physicians, and the expansion of PureTech’s senior team.
Cipla launching low-dose Efavirenz 400 mg HIV infection therapy
Teva and Takeda are forming a new joint venture to operate in Japan
“Ours will be the last generation to see the horror of children paralyzed or killed by polio. I am sure,” said Pr Jacob John, Former Christian Medical College, Vellore, Tamil Nadu, India.
“Maybe we will remember 2015 as the year we took the final step to eradicate this disease forever.”